EFR3A Inhibitors
EFR3A inhibitors are a class of chemical compounds that primarily target the EFR3A protein, which is involved in various cellular signaling pathways. EFR3A, also known as EFR3 homolog A or EFR3 lipid raft-associated phosphoprotein, is a crucial regulator of cellular processes, including cell growth, division, and migration. Inhibitors of EFR3A are designed to modulate its activity by interfering with its function within the cell. These inhibitors typically act through direct binding to the EFR3A protein or by affecting its downstream signaling cascades. By doing so, they influence intracellular processes and have the ability to impact cellular behavior.
The mechanism of action of EFR3A inhibitors often involves their interaction with specific regions of the protein, such as its kinase domain or ATP-binding site. This interaction disrupts the normal functioning of EFR3A, preventing its autophosphorylation and the subsequent activation of downstream signaling pathways. As a result, EFR3A inhibitors can inhibit cell proliferation, migration, and survival in certain contexts. These compounds are valuable tools for researchers studying cellular signaling pathways uncover new insights into the role of EFR3A in various biological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets EFRA3 by binding to its active site, blocking autophosphorylation and downstream signaling, thereby inhibiting the growth of cancer cells in chronic myeloid leukemia. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
AP 24534 is a potent EFRA3 inhibitor that binds to its ATP-binding site, blocking phosphorylation and inhibiting the growth of cancer cells, especially in drug-resistant cases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits EFRA3 by binding to its kinase domain, disrupting signaling pathways and blocking the growth of cancer cells, particularly in chronic myeloid leukemia. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib targets EFRA3 by inhibiting its autophosphorylation and downstream signaling, which helps slow the progression of non-small cell lung cancer by inhibiting cell growth and division. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EFRA3 by blocking its ATP-binding site, reducing phosphorylation and downstream signaling, leading to the suppression of cell proliferation, especially in lung cancer. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits EFRA3 by binding to its kinase domain, disrupting signal transduction, and inhibiting the growth of cancer cells, particularly in HER2-positive breast cancer. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib inhibits EFRA3 by targeting its ATP-binding site, preventing autophosphorylation, and inhibiting the proliferation of cancer cells, particularly in chronic myeloid leukemia. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib targets EFRA3 by blocking its autophosphorylation and downstream pathways, which inhibits the growth of cancer cells, especially in medullary thyroid cancer. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Afatinib inhibits EFRA3 by covalently binding to its kinase domain, disrupting signaling, and inhibiting cell proliferation, particularly in EGFR-mutated non-small cell lung cancer. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib selectively inhibits EFRA3 in EGFR-mutated lung cancer cells, preventing phosphorylation and downstream signaling, leading to the suppression of cancer cell growth. | ||||||